From: Developing preclinical models of neuroblastoma: driving therapeutic testing
Cell Line | MYCN Status | ALK Mutation | P53 mutation | Preclinical Testing References |
---|---|---|---|---|
KELLY | Amplified | WT | WT | |
CHP-212 | Amplified | WT | WT | |
SKNAS | Non-Amplified | WT | H168R | |
SH-SY-5Y | Non-Amplified | F1174 L | WT | |
IMR-32 | Amplified | WT | WT | |
IMR-05 | Amplified | WT | WT | |
LA-N-5 | Amplified | R1275Q | WT | |
NB-1 | Amplified | WT; Amplified | WT | |
SK-N-BE(2) | Amplified | WT | C135F | |
SK-N-BE(2)-C | Amplified | WT | C135F | [78] |
CHP-134 | Amplified | WT | WT | |
SK-N-DZ | Amplified | WT | R110L | |
NB-1691 | Amplified | WT | WT |